Contact Us

Your one-stop shop for everything ACCRUFeR^®

Whether you need clinical information about ACCRUFeR (ferric maltol) or want to learn about access, you can find what you're looking for below.

* Required

First name

Last name

E-mail address to receive more information about ACCRUFeR

Phone number

ZIP code

Company

NPI number

I want to hear about:

Tolerability

How ACCRUFeR works

Access and affordability

Dosing

In-person visit

Samples

I certify that I am at least 18 years of age, and want to receive information from Shield Therapeutics, and third parties working on behalf of Shield Therapeutics. I agree that Shield Therapeutics may use the information I provide to send me health-related materials, as well as information on Shield Therapeutics products and services, including marketing programs. Shield Therapeutics may also use my information for market research or to evaluate and improve the company’s programs and services.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

ACCRUFeR is contraindicated in patients with a history of:

Hypersensitivity to ACCRUFeR or any of its inactive components

Hemochromatosis and other iron overload syndromes

Receiving repeated blood transfusions as this may result in iron overload

WARNINGS AND PRECAUTIONS

Increased Risk of Inflammatory Bowel Disease (IBD) Flares

Avoid use of ACCRUFeR in patients with an active IBD flare, as there is potential risk of increased inflammation in the gastrointestinal tract.

Iron Overload

Excessive therapy with iron products can lead to excess storage of iron with the possibility of iatrogenic hemosiderosis. Do not administer ACCRUFeR to patients with evidence of iron overload or patients receiving intravenous iron. Assess iron parameters prior to initiating ACCRUFeR and monitor iron parameters while on therapy.

Risk of Overdosage in Children Due to Accidental Ingestion

Accidental overdose of iron products is a leading cause of fatal poisoning in children under age 6. Keep out of reach of children.